Showing results (81-90 of 280) with videos related to

Sort By:
Pageof 28
Haematologica|November 13, 2012
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adultsDan P Zandberg, Ting-Ying Huang, Xuehua Ke, et al.
Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.
Cancer|March 13, 2016
Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesAmer M Zeidan, Rong Wang, Amy J Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Blood Reviews|January 24, 2015
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyLin Mei, Evelena P Ontiveros, Elizabeth A Griffiths, et al.
Expert Opinion on Biological Therapy|May 20, 2015
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesBritny Rogala, Craig W Freyer, Evelena P Ontiveros, et al.
Cancer|June 23, 2017
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantationLucy Hui, Gottfried von Keudell, Rong Wang, et al.
Journal of Oncology Practice|January 8, 2015
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part DAmy J Davidoff, Franklin B Hendrick, Amer M Zeidan, et al.
Research Square|June 5, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroidsBeverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Cancer Chemotherapy and Pharmacology|September 12, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroidsBeverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Pageof 28